BioAge Labs Doses First Patient in Phase 2 Trial of BGE-102 in Diabetic Macular Edema

10:01 AM EDT, 09/08/2026 (MT Newswires) -- BioAge Labs (BIOA) said Tuesday it has dosed the first participant in its phase 2 trial of BGE-102 in adults with diabetic macular edema. The trial will evaluate BGE-102, a once-daily oral NLRP3 inhibitor, both as monotherapy and as add-on to standard-of-care anti-VEGF therapy, with about 180 participants, the company said. The primary endpoint is change in best-corrected visual acuity at week 12, BioAge Labs said. Topline results are expected in H2 of 2027, the company added. Price: 9.52, Change: -0.07, Percent Change: -0.77